Sanofi Sa · EURONEXT:SAN
Sanofi Sa — 44th Annual J.P. Morgan Healthcare Conference 2026
7 slides from Sanofi Sa's conference presentation, Jan 12, 2026
Slide 1: Sanofi
sanofi
Slide 2: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference San Francisco, CA, USA January 12, 2026
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlyin
Slide 4: 2025: strategic progress
2025: strategic progress Strategy Business Pipeline R&D-driven, AI-powered biopharmaceutical company 8.7% Three new medicines and vaccines launched: Qfitlia (haemophilia), committed to improving people’s lives growth in sales YTD2 Wayrilz (ITP4), Nuvaxovid (COVID-195) and delivering compelling growt
Slide 5: Pipeline: key mid- and late-stage development projects
Pipeline: key mid- and late-stage development projects Immunology Rare diseases/Oncology Neurology Vaccines phase 3 AD approved IT P (US, EU) amli teli mab Wayrilz tol ebru tini b und er revi ew SPMS (EU) Fluzone HD phas e 3 flu 5 0 years+ pot ential LCM pot ential LCM phas e 2 ast hma lun sekimig e
Slide 6: Pipeline: upcoming news flow
Pipeline: upcoming news flow amli teli mab – AD (full data) frexal imab – RMS Nexviazyme – IOPD brivekimig – HS ri liprubart – CIDP lun sekimig – ast hma vengl ustat – Fabry d iseas e it epekimab – CRSwNP SP02 02 – PCV SP02 30 – meningit is* vengl ustat – GD3 Du pixent – LSC fit usiran – hemop hili
Slide 7: Sanofi
sanofi
Sanofi — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix